Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke(University Medical Center), Martin Schrappe(University Hospital Schleswig-Holstein)
Cited by 607